No Data
No Data
North China Pharmaceutical (600812.SH) will distribute a dividend of 0.01 yuan per share for the year 2023, with a record date of July 17th.
North China Pharmaceutical (600812.SH) announced that the company will implement the annual equity distribution for 2023, distributing per share...
Announcement of expected increase in performance for the first half of 2024.
North China Pharmaceutical (600812.SH): Net income for the first half of the year is expected to increase by about 164% compared to the same period last year.
On July 10th, Gelunhui reported that North China Pharmaceutical (600812.SH) announced its performance forecast for the first half of 2024. The initial estimation by the financial department predicts that the net income attributable to the owners of the parent company will be around 70 million yuan, an increase of about 43.45 million yuan compared to the same period last year, a year-on-year increase of about 164%. The estimated net profit attributable to the owners of the parent company excluding non-recurring gains and losses will be around 52 million yuan, an increase of about 50.94 million yuan compared to the same period last year, a year-on-year increase of about 4,810%. The company achieves this through.
North China Pharmaceutical (600812.SH): Subsidiary receives government subsidy of 1.005 million yuan
On July 9th, Gelonhui reported that North China Pharmaceutical (600812.SH) announced that its subsidiary received a total of RMB 1.005 million in government subsidies related to revenue from July 1, 2024, to the date of this announcement, accounting for 20.55% of the net income attributable to shareholders of listed companies in 2023.
North China Pharmaceutical (600812.SH): Subsidiary receives government subsidy of 1.1 million yuan.
On June 24, Gelunhui reported that North China Pharmaceutical (600812.SH) and its subsidiaries received a total of 1,100,000.00 yuan in government subsidies related to income from June 17, 2024 to the date of this announcement. This accounts for 22.49% of the net income attributable to shareholders of the listed company in 2023.
North China Pharmaceutical Company.Ltd's (SHSE:600812) Business And Shares Still Trailing The Industry
North China Pharmaceutical Company.Ltd's (SHSE:600812) price-to-sales (or "P/S") ratio of 0.7x might make it look like a strong buy right now compared to the Pharmaceuticals industry in China, where a
No Data